GlassScriptPhysician profile
Eric N Sorensen
NPI 1063521896
$4,927.62
in general payments reported to CMS, 2019-2025
42 companies · $307 in 2025
The $307 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $868 · 2020: $362 · 2021: $1,033 · 2022: $984 · 2023: $819 · 2024: $555 · 2025: $307.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,595 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,595.48 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $442.00 | 2021-2025 | Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $419.70 | 2019-2024 | Jardiance |
| Abbvie INC. | $387.42 | 2021-2024 | Ubrelvy |
| Amarin Pharma, INC. | $373.90 | 2019-2021 | |
| Lilly USA, LLC | $346.39 | 2019-2025 | Mounjaro, Emgality, Jardiance |
| Amgen INC. | $262.66 | 2019-2025 | Otezla, Repatha, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $262.33 | 2021-2022 | |
| Astellas Pharma US INC | $223.53 | 2019-2024 | Veozah |
| Glaxosmithkline, LLC. | $218.11 | 2020-2024 | Trelegy Ellipta |
| Pfizer INC. | $199.99 | 2019-2025 | |
| Esperion Therapeutics, INC. | $196.17 | 2020-2023 | Nexletol |
| Biohaven Pharmaceutical Holding Company LTD. | $179.06 | 2022 | |
| Novartis Pharmaceuticals Corporation | $146.98 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $146.17 | 2019-2025 | Airsupra |
| Abiomed | $120.94 | 2023 | Impella |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Sorensen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.